PET/MRI for evaluation of patients with pancreatic cancer.
Zoey N DuncanDavid SummerlinJanelle T WestAnnie T PackardDesiree E MorganSamuel J GalganoPublished in: Abdominal radiology (New York) (2023)
Pancreatic cancers are the third leading cause of cancer-related death in the USA and outcomes remain poor despite improvements in imaging and treatment paradigms. Currently, computed tomography (CT) and magnetic resonance imaging (MRI) are frequently utilized for staging and restaging of these malignancies, but positron emission tomography (PET)/CT can play a role in troubleshooting and improve whole-body staging. PET/MRI is a novel imaging modality that allows for simultaneous acquisition of PET and MRI images, leading to improved image quality and potential increased sensitivity. Early studies suggest that PET/MRI may play a larger role in pancreatic cancer imaging in future. This manuscript will briefly discuss current imaging approaches to pancreatic cancer and outline existing evidence and published data supporting the use of PET/MRI for pancreatic cancers.
Keyphrases
- positron emission tomography
- computed tomography
- contrast enhanced
- pet ct
- magnetic resonance imaging
- image quality
- dual energy
- high resolution
- diffusion weighted imaging
- pet imaging
- machine learning
- magnetic resonance
- deep learning
- big data
- lymph node
- metabolic syndrome
- photodynamic therapy
- risk assessment
- artificial intelligence
- electronic health record
- convolutional neural network